Entact Bio Revenue and Competitors

Boston, MA USA

Location

$127M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Entact Bio's estimated annual revenue is currently $4M per year.(i)
  • Entact Bio's estimated revenue per employee is $77,500
  • Entact Bio's total funding is $127M.

Employee Data

  • Entact Bio has 51 Employees.(i)
  • Entact Bio grew their employee count by 6% last year.

Entact Bio's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
SVP, Biological SciencesReveal Email/Phone
4
SVP Corporate Development and StrategyReveal Email/Phone
5
SVP, Corporate Development & StrategyReveal Email/Phone
6
Head OperationsReveal Email/Phone
7
SVP, Molecular DiscoveryReveal Email/Phone
8
Executive Director, Molecular DiscoveryReveal Email/Phone
9
Director, Data ScienceReveal Email/Phone
10
DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Entact Bio?

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

keywords:N/A

$127M

Total Funding

51

Number of Employees

$4M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.7M5111%N/A
#2
$22.4M5241%N/A
#3
$13.6M520%N/A
#4
$10.9M54-60%N/A
#5
$13.6M54-25%N/A